Premium
CHOP or THP‐COP regimens in the treatment of newly diagnosed peripheral T‐cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin
Author(s) -
Shibata Yuhei,
Hara Takeshi,
Kasahara Senji,
Yamada Toshiki,
Sawada Michio,
Mabuchi Ryoko,
Matsumoto Takuro,
Nakamura Nobuhiko,
Nakamura Hiroshi,
Ninomiya Soranobu,
Kitagawa Junichi,
Kanemura Nobuhiro,
Kito Yusuke,
Goto Naoe,
Miyazaki Tatsuhiko,
Takami Tsuyoshi,
Takeuchi Tamotsu,
Shimizu Masahito,
Tsurumi Hisashi
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2262
Subject(s) - pirarubicin , medicine , chop , vincristine , international prognostic index , gastroenterology , anthracycline , regimen , doxorubicin , lymphoma , cyclophosphamide , chemotherapy , cancer , breast cancer
Abstract The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS). Pirarubicin [tetrahydropyranyladriamycin (THP)], a derivative of DOX, is an anthracycline with reportedly less cardiotoxicity than DOX. Here, we confirmed the efficacy of THP‐COP using THP instead of DOX in the treatment of PTCL‐NOS. The study protocol employed a retrospective, consecutive entry design. We retrospectively analysed 56 patients with PTCL‐NOS who had received THP‐COP or CHOP. These regimens were performed every 21 days. Twenty‐nine patients received THP‐COP, and 27 received CHOP. There were no significant differences in known prognostic factors, including in the International Prognostic Index (IPI) and the prognostic index for T‐cell lymphoma (PIT), between the two groups. Complete remission rates in patients with THP‐COP and CHOP were 52% in both groups; the 3‐year overall survival (OS) rates were 67% and 52% ( p = 0.074), and the 3‐year progression‐free survival (PFS) rates were 51% and 29% ( p = 0.070), respectively. In patients with low IPI (low or low‐intermediate), THP‐COP had significantly better 3‐year OS (100% vs. 64%; p < 0.001) and 3‐year PFS (75% vs. 33%; p < 0.05) than CHOP. Similar differences between THP‐COP and CHOP were observed in patients with a low PIT (groups 1 or 2). Our study showed that THP‐COP produced results equivalent to CHOP regarding efficacy and safety in patients with PTCL‐NOS. In patients with low IPI or PIT, THP‐COP resulted in significantly better prognosis. Copyright © 2015 John Wiley & Sons, Ltd.